Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm study of iparomlimab + tuvonralimab with paclitaxel and cisplatin/carboplatin for persistent cervical cancer after concurrent chemoradiotherapy
ChiCTR2600132217Phase 2Not yet recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- Aug 2026
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of iparomlimab, tuvonralimab, paclitaxel, cisplatin and carboplatin in Cervical Cancer (CC), sponsored by Henan Cancer Hospital. Primary endpoint: 1-year progression-free survival rate. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
iparomlimabtuvonralimabpaclitaxelcisplatincarboplatin
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on ChiCTR2600132217.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600132217.